Latest Headlines

  1. Thermo Fisher Scientific's Oncomine Dx Target Test Receives FDA Approval As A Companion Diagnostic To Identify Patients Eligible For Newest Targeted Therapy For Non-Small Cell Lung Cancer 11/20/2025

    Thermo Fisher Scientific, the world leader in serving science, has received approval from the U.S. Food and Drug Administration (FDA) for its Ion Torrent Oncomine Dx Target Test as a companion diagnostic (CDx) to identify patients who may be eligible for treatment with HYRNUO (sevabertinib), a new HER2-directed therapy developed and commercialized by Bayer.

  2. Abbott To Acquire Exact Sciences, A Leader In Large And Fast-Growing Cancer Screening And Precision Oncology Diagnostics Segments 11/20/2025

    Abbott (NYSE: ABT) and Exact Sciences (NASDAQ: EXAS) today announced a definitive agreement for Abbott to acquire Exact Sciences, which will enable it to enter and lead in fast-growing cancer diagnostics segments, serving millions more people.

  3. SPT Labtech Enables Automated PacBio Kinnex Full-Length RNA-seq Library Preparation Workflow On SPT's Firefly Platform 11/20/2025

    SPT Labtech, a global leader in the design and development of laboratory automation and liquid handling solutions, today announced a collaboration with Pacific Biosciences (PacBio), a pioneer in long-read sequencing, to automate PacBio's Kinnex full-length RNA-seq library preparation on SPT Labtech’s firefly liquid handling platform.

  4. KHB Highlights The Polaris V150 Automatic Chemiluminescence Immunoassay Analyzer At MEDICA 2025 11/19/2025

    Shanghai Kehua Bio-engineering Co., Ltd. (KHB), a global provider of in-vitro diagnostic (IVD) solutions, is showcasing its latest compact chemiluminescence platform—the Polaris V150 Automatic Chemiluminescence Immunoassay Analyzer—at MEDICA 2025, one of the world's leading medical industry exhibitions. As a featured product at this year's KHB booth, the Polaris V150 demonstrates the company's continuous innovation in automated diagnostics.

  5. Parse Biosciences Announces FFPE-Compatible Barcoding Technology For Whole Transcriptome Single Cell Analysis 11/18/2025

    Parse Biosciences, the leading provider of scalable and accessible single cell sequencing solutions, today announced a breakthrough technology that unlocks the full potential of formalin-fixed, paraffin-embedded (FFPE) samples.

  6. Nanopath Granted FDA Breakthrough Device Designation For Its Molecular Diagnostic Platform For Urinary Tract Infections 11/18/2025

    Nanopath, a point-of-care diagnostics company enabling high-quality molecular testing in minutes, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device designation for the company's novel assay for the rapid detection of infection in patients with suspected, or at risk of, complicated urinary tract infections (UTIs).

  7. Hyland And Tribun Health Partner To Deliver Next-Generation, Intelligent Digital Pathology 11/18/2025

    Hyland, the pioneer of the Content Innovation Cloud™, and Tribun Health, a leader in digital pathology, have joined forces to advance pathology workflows by integrating Tribun Health's advanced platform with Hyland's enterprise imaging solutions.

  8. Freenome Announces Exclusive Agreement With Roche To Expand Technology Collaboration And Develop And Commercialize Cancer Screening Tests Outside The U.S. 11/18/2025

    Freenome, an early cancer detection company developing blood-based screening tests, today announced a strategic collaboration agreement with Roche to commercialize Freenome's cancer screening technology in international markets.

  9. UPDATE – PrognomiQ Launches ProVue Lung, A Proteomics-Based Laboratory Developed Test To Aid In The Early Detection Of Lung Cancer 11/18/2025

    PrognomiQ, a healthcare company focused on harnessing the power of proteomics and multi-omics data to transform the detection and early treatment selection and monitoring of cancer and other complex diseases, today announced the launch of ProVue Lung, a novel blood-based Laboratory Developed Test (LDT) designed to help improve detection of lung cancer at its earliest, most treatable stages.

  10. Augurex Life Sciences Corp. Announces The Launch Of The 14-3-3eta Test For Rheumatoid Arthritis Diagnosis And Monitoring With Sonic Reference Laboratory 11/17/2025

    Augurex Life Sciences Corp., a leader in the development of autoimmune-based diagnostics, today announced the upcoming launch of the 14-3-3eta test, approved as JOINTstat in Canada and the UK, through Sonic Reference Laboratory, a division of Sonic Healthcare USA.